Muscle Invasive (MIBC)

FDA Approves Perioperative Enfortumab Vedotin-ejfv Plus Pembrolizumab for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Phase III KEYNOTE-B15: Perioperative Enfortumab Vedotin-ejfv + Pembrolizumab Improves Outcomes in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Phase III KEYNOTE-B15 data demonstrate significant improvements in event-free survival (EFS), overall survival (OS) and pathologic complete response (pCR) rates compared with standard cisplatin-based perioperative...

Latest Posts

A New Era in MIBC: Perioperative Pembrolizumab + Enfortumab Vedotin Approved for Cisplatin-Ineligible Patients

On November 21, 2025, the U.S. Food and Drug Administration approved pembrolizumab (Keytruda or Keytruda...

IMvigor011: Signatera™ ctDNA Testing Guides Adjuvant Atezolizumab Benefit in Muscle-Invasive Bladder Cancer

Signatera-positive patients treated with atezolizumab had statistically significant improvements in disease-free and overall survival.

KEYNOTE-905: First Perioperative Therapy to Demonstrate Survival Benefit in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

First positive Phase 3 trial shows perioperative immunotherapy combination addresses critical gap for cisplatin-ineligible patients.

Economic Analysis: Trimodal Therapy vs Radical Cystectomy Cost-Effectiveness in Muscle-Invasive Bladder Cancer

TMT was not cost-effective at 5-year (ICER, $464,291 per QALY) or 10-year (ICER, $308,638 per...

Phase III IMvigor011 Trial Validates ctDNA-Guided Adjuvant Immunotherapy in Bladder Cancer

IMvigor011 trial shows Signatera ctDNA test predicts which bladder cancer patients benefit from adjuvant atezolizumab...

KEYTRUDA plus Padcev Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

First systemic therapy to improve survival when used before/after surgery for MIBC patients ineligible for...

Urothelial Carcinoma Insight Center

Non-Muscle Invasive (NMIBC)

About
Contact
Privacy Policy
Terms of Use

About
Contact
Privacy Policy
Terms of Use

732-455-2192
contact@oncologynexus.com

Facebook-f Twitter Google-plus-g Pinterest